Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population
- PMID: 27660057
- DOI: 10.1007/s00439-016-1728-9
Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population
Abstract
Recently, a single nucleotide polymorphism (SNP) A503V (rs1057868) in cytochrome P450 oxidoreductase (POR) gene was reported to influence nicotine metabolism. Considering the importance of nicotine metabolism to smoking cessation, the aim of this study was to investigate the association between POR gene polymorphisms and smoking cessation in a Chinese population. A case-control study was conducted with 363 successful smoking quitters as the cases, and 345 failed smoking quitters as the controls. Eight tagSNPs which cover the entire gene and four functional SNPs were selected and genotyped. Logistic regression was used to explore the relationship between POR SNPs and smoking cessation in codominant, additive, dominant and recessive models. After adjustment for potential confounders, multiple logistic regression analysis indicated that POR rs3823884 and rs3898649 were associated with increased possibility of smoking cessation. Meanwhile, POR rs17685 and rs239953 were shown to have negative effect on successful smoking cessation. No significant differences in the distribution of haplotypes between cases and controls were detected. In conclusion, this study reveals that four SNPs in the POR gene (rs3823884, rs3898649, rs239953 and rs17685) may affect the susceptibility of smoking cessation in a Chinese Han population.
Similar articles
-
Association of POR and PPARα polymorphisms with risk of anti-tuberculosis drug-induced liver injury in Western Chinese Han population.Infect Genet Evol. 2020 Apr;79:104147. doi: 10.1016/j.meegid.2019.104147. Epub 2019 Dec 16. Infect Genet Evol. 2020. PMID: 31857256
-
Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement.Eur J Clin Pharmacol. 2013 Oct;69(10):1769-75. doi: 10.1007/s00228-013-1544-2. Epub 2013 Aug 16. Eur J Clin Pharmacol. 2013. PMID: 23949431 Clinical Trial.
-
Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption.Pharmacogenet Genomics. 2014 Mar;24(3):172-6. doi: 10.1097/FPC.0000000000000031. Pharmacogenet Genomics. 2014. PMID: 24448396 Free PMC article.
-
Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.Fundam Clin Pharmacol. 2007 Aug;21(4):399-410. doi: 10.1111/j.1472-8206.2007.00520.x. Fundam Clin Pharmacol. 2007. PMID: 17635179 Review.
-
P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):439-52. doi: 10.1517/17425255.4.4.439. Expert Opin Drug Metab Toxicol. 2008. PMID: 18433346 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical